Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to demonstrate whether a switch from insulin therapy to an oral
therapy with pioglitazone/glimepiride will lead to a deterioration of glycemic control
(increase in HbA1c by more than 0.5 %) within a 6 month observation period.
Phase:
Phase 4
Details
Lead Sponsor:
IKFE Institute for Clinical Research and Development